JP Morgan Private Wealth Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-30,442	Closed	-$154K	–	1528
2019 Q3	$154K	Buy	30,442 +2,228	+8%	+$11.1K	﹤0.01%	1369
2019 Q2	$174K	Sell	28,214 -490	-2%	-$2.36K	﹤0.01%	1308
2019 Q1	$133K	Buy	28,704 +694	+2%	+$3.14K	﹤0.01%	1399
2018 Q4	$118K	Sell	28,010 -758	-3%	-$3.86K	﹤0.01%	1383
2018 Q3	$180K	Buy	28,768 +1,831	+7%	+$14.1K	﹤0.01%	1490
2018 Q2	$217K	Buy	26,937 +4,652	+21%	+$35.5K	﹤0.01%	1337
2018 Q1	$166K	Buy	22,285 +483	+2%	+$3.21K	﹤0.01%	1199
2017 Q4	$130K	Buy	21,802 +2,525	+13%	+$15.3K	﹤0.01%	1219
2017 Q3	$142K	Buy	19,277 +3,678	+24%	+$23.4K	﹤0.01%	1182
2017 Q2	$106K	Buy	15,599 +1,027	+7%	+$7.58K	﹤0.01%	1184
2017 Q1	$138K	Buy	+14,572	New	+$145K	﹤0.01%	1281

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Private Wealth Advisors's PGNX Position: Q4 2019 in Review

JP Morgan Private Wealth Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 30,442 shares — an estimated $154K sold.

JP Morgan Private Wealth Advisors first reported a position in PGNX in Q1 2017 and held it in 11 quarters. The position peaked at $217K in Q2 2018. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

JP Morgan Private Wealth Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
JP Morgan Private Wealth Advisors sold 30,442 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $154K.
JP Morgan Private Wealth Advisors first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 11 quarters.
JP Morgan Private Wealth Advisors's Progenics Pharmaceuticals Inc position peaked at $217K in Q2 2018.
128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.